| Literature DB >> 26648712 |
Marceli Rocha Leite1, Ercy Mara Cipulo Ramos1, Carlos Augusto Kalva-Filho2, Ana Paula Coelho Figueira Freire1, Bruna Spolador de Alencar Silva1, Juliana Nicolino1, Alessandra Choqueta de Toledo-Arruda3, Marcelo Papoti4, Luiz Carlos Marques Vanderlei1, Dionei Ramos1.
Abstract
INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) exhibit aerobic function, autonomic nervous system, and mucociliary clearance alterations. These parameters can be attenuated by aerobic training, which can be applied with continuous or interval efforts. However, the possible effects of aerobic training, using progressively both continuous and interval sessions (ie, linear periodization), require further investigation. AIM: To analyze the effects of 12-week aerobic training using continuous and interval sessions on autonomic modulation, mucociliary clearance, and aerobic function in patients with COPD.Entities:
Keywords: COPD; aerobic treatment; exercise; mucociliary clearance
Mesh:
Year: 2015 PMID: 26648712 PMCID: PMC4664442 DOI: 10.2147/COPD.S81363
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Figure 1Flow diagram showing the participation of the patients in the study.
Figure 2Time spent in each intensity zone during the 12 weeks of aerobic training.
Notes: Z1: 60% of VO2peak for 50 minutes (continuous effort); Z2: 75% of VO2peak for 30 minutes (continuous effort); Z3: five efforts lasting 3 minutes separated by 1 minute of passive recovery (interval effort).
Abbreviation: VO2peak, peak oxygen uptake.
Anthropometric data and pulmonary function of the assessed patients expressed in median (interquartile range 25%–75%)
| AT (n=10) | CG (n=6) | ||
|---|---|---|---|
| Age (years) | 62 (60.25–69.25) | 62.5 (57.25–70.5) | 0.8543 |
| Anthropometric | |||
| Height (cm) | 165 (154.3–173) | 165 (157–168.5) | 0.9851 |
| Weight (kg) | 74.4 (64–87) | 70.7 (65.25–78) | 0.5102 |
| BMI (kg·[m2]−1) | 27.6 (21.83–32.54) | 26.85 (23–30.88) | 0.9578 |
| Spirometrics | |||
| FEV1 (%pred) | 55 (39–70) | 45 (37.65–73.63) | 0.8749 |
| FVC (%pred) | 78 (66.25–83.48) | 86.61 (61.8–101.8) | 0.7925 |
| FEV1/FVC | 56 (46.78–65.7) | 48.1 (41.1–66.05) | 0.5104 |
Abbreviations: AT, aerobic training group; CG, control group; BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; (%pred), percentage of predicted values.
Aerobic parameters of aerobic training group (AT) and control group (CG), observed at baseline (M0) and after 12 weeks (M1) expressed in median (interquartile range 25%–75%)
| AT (n=10)
| CG (n=6)
| |||
|---|---|---|---|---|
| M0 | M1 | M0 | M1 | |
| VO2peak (L·min−1) | 0.63 (0.4–1) | 1.83 (1.3–2.7) | 0.56 (0.5–0.5) | 0.6 (0.4–0.3) |
| VO2peak (mL·kg−1·min−1) | 10 (6.2–13) | 26.28 (14.9–33.6) | 7.7 (7.6–7.5) | 7.9 (6.1–3.9) |
| vVO2peak (km·h−1) | 6 (4.2–6.4) | 6.4 (5.2–7.5) | 4.8 (4.5–4.5) | 4.5 (4–3.2) |
| GET (km·h−1) | 3.25 (2.6–3.5) | 4.5 (3.1–4.9) | 3.0 (3–2.5) | 3.0 (3–2.5) |
| GET (mL·kg−1·min−1) | 0.34 (0.2–0.6) | 0.9 (0.7–1.8) | 0.4 (0.3–0.3) | 0.3 (0.3–0.2) |
Notes:
Significant difference between M0 and M1 (P<0.05);
significant difference between AT and CG at M1.
Abbreviations: VO2peak, peak oxygen uptake; vVO2peak, velocity corresponding to VO2peak; GET, gas exchange threshold.
Heart rate variability indexes of aerobic training group (AT) and control group (CG), observed at baseline (M0) and after 12 weeks (M1) expressed in median (interquartile range 25%–75%)
| AT (n=10)
| CG (n=6)
| |||
|---|---|---|---|---|
| M0 | M1 | M0 | M1 | |
| SDNN (ms) | 19.84±6.21 | 24.87±8.6 | 19.17±4.95 | 18.9±5.7 |
| 20.35 (14.7–25.23) | 25 (20.08–32.55) | 18.9 (15.28–23.53) | 19.25 (13.13–24.25) | |
| RMSSD (ms) | 14.15±5.69 | 18.28±6.22 | 13.47±7.89 | 15.02±8.12 |
| 14.15 (9.15–20.3) | 20.05 (13.73–22.98) | 12.65 (7.1–16.88) | 12.25 (10–20.78) | |
| LF (ms2) | 146.1±118.9 | 177.7±125.6 | 130.7±49 | 101±40.36 |
| 97.5 (56–237.8) | 161.5 (79.5–267.8) | 121 (86.5–174.5) | 92.5 (71–125.8) | |
| LF (nu) | 67.47±15.96 | 58.48±13.62 | 69.65±19.8 | 66.43±16.36 |
| 70.8 (55–79) | 57.75 (52.8–70.4) | 72.1 (49.4–87.83) | 64.05 (52.03–83.25) | |
| HF (ms2) | 62.3±46.84 | 113.2±62.19 | 60.17±39.98 | 61.17±48.33 |
| 49.5 (20–107.5) | 109 (66.25–158.8) | 69 (15.25–93) | 53.5 (16.75–105.3) | |
| HF (nu) | 32.63±15.9 | 41.52±13.62 | 30.35±19.8 | 33.57±16.36 |
| 29.7 (20.75–44.3) | 42.25 (29.6–47.2) | 27.9 (12.18–50.6) | 35.95 (16.75–47.98) | |
| LF/HF | 2.9±2.2 | 1.62±0.77 | 4.5±4.79 | 2.91±2.43 |
| 2.5 (1.2–3.8) | 1.36 (1.12–2.37) | 2.82 (0.98–7.97) | 1.91 (1.09–5.14) | |
Note:
Significant difference between M0 and M1 (P<0.05).
Abbreviations: SDNN, standard deviation of the mean of all normal RR intervals; RMSSD, root mean square of differences between adjacent normal RR intervals in a time interval; LF, spectral component of low frequency; HF, spectral component of high frequency; nu, normalized units.
Figure 3Box plot of saccharin transit time (STT) test of the aerobic training group (AT) and the no-training control group (CG), observed at baseline (M0) and after 12 weeks (M1).